Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Sycamore Mid Cap Value Equity Gary H. Miller | “Shares declined due to negative sentiment surrounding conservative government and academic research funding. However, the company remains fundamentally strong and positioned to benefit from a recovery in biotech funding and pharmaceutical deals.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “Revvity We invested in the former PerkinElmer in the wake of Covid. In many ways we are in a new golden age for medicine—the growth of biologics and peptides, new frontiers in personalized medicine, AI to identify actionable therapies, mRNA to deliver them—and Revvity, which makes the consumables used in both research facilities and customer- facing diagnostics, seemed like a good platform. Unfortunately, management spent its Covid testing windfall on overpriced acquisitions while divesting its cash-generative but less exciting food testing division, and then was left flat-footed when pharma research spending stalled and the FDA dramatically reduced science spending. Our overall return was -28.5%, or a -5.90% IRR, but the most painful loss was our opportunity cost. BSD Analysis: Revvity has successfully pivoted into a high-growth pure-play in the diagnostics and life sciences research markets. The company's focus on high-margin automated workflows and specialized genomic testing is beginning to yield fruit, evidenced by a strong pipeline and positive earnings revisions. While academic research funding has shown some global softness, Revvity's diagnostics segment remains a robust driver of recurring revenue and free cash flow. Management's recent approval of a significant share buyback program signals confidence in the stock's intrinsic value and its long-term growth trajectory. As healthcare systems increasingly move toward personalized medicine and early disease detection, Revvity is well-positioned to capture increasing demand for its innovative health science solutions.” | BEAR | Q4 2025 Feb 12, 2026 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “Revvity successfully restructured post-pandemic by divesting lower-margin assets to build specialized diagnostic and research reagent franchises. The company trades at reasonable earnings multiples while maintaining market leadership across newborn screening and immunodiagnostics.” | BULL | Q4 2024 Dec 31, 2024 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
